The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1043-1050 , November 2007

Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma

  • Stanley J. Szefler, MD

      Affiliations

    • Division of Pediatric Clinical Pharmacology and Allergy/Immunology, National Jewish Medical and Research Center, and the Departments of Pediatrics and Pharmacology, University of Colorado Health Sciences Center, Denver, Colo
    • Corresponding Author InformationReprint requests: Stanley J. Szefler, MD, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206.
    • ,
  • James W. Baker, MD

      Affiliations

    • Allergy Associates PC, Portland, Ore
    • ,
  • Tom Uryniak, MS

      Affiliations

    • AstraZeneca LP, Wilmington, Del
    • ,
  • Mitchell Goldman, MD, PhD

      Affiliations

    • AstraZeneca LP, Wilmington, Del
    • ,
  • Philip E. Silkoff, MD

      Affiliations

    • AstraZeneca LP, Wilmington, Del

Received 3 May 2007 ,Revised 8 August 2007 ,Accepted 29 August 2007.

  • Image Result

    Study flow chart. PE, Physical examination; PEFM, PEF meter.

    Study flow chart. PE, Physical examination; PEFM, PEF meter.

  • Image Result

    Subject disposition.

    Subject disposition.

  • Image Result

    Kaplan-Meier probability curve for the time to first additional asthma medication (step-up BIS or oral corticosteroids) over the 52-week study period. ∗Unadjusted P = .05.

    Kaplan-Meier probability curve for the time to first additional asthma medication (step-up BIS or oral corticosteroids) over the 52-week study period. ∗Unadjusted P = .05.

 Supported by AstraZeneca LP.

 Disclosure of potential conflict of interest: S. J. Szefler has consulting arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received grant support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, and Ross Pharmaceuticals. J. W. Baker has received grant support from GlaxoSmithKline, AstraZeneca, Apieron, NIOXX, Sanofi-Aventis, Amgen, ALK, Altana, MedPointe, Centocor, IVAX, JNJ, and Wyeth and is on the speakers' bureau for AstraZeneca, Novartis, and Merck. T. Uryniak, M. Goldman, and P. E. Silkoff own stock in and are employed by AstraZeneca.

PII: S0091-6749(07)01726-5

doi: 10.1016/j.jaci.2007.08.063

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1043-1050 , November 2007

Article Tools

* Image Usage & Resolution